- Immune cells in cancer
- Chemokine receptors and signaling
- Acute Myeloid Leukemia Research
- Inflammation biomarkers and pathways
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Immunodeficiency and Autoimmune Disorders
- RNA regulation and disease
- Blood disorders and treatments
- Immune Cell Function and Interaction
- Congenital Diaphragmatic Hernia Studies
The Ohio State University
2023
University of New Orleans
2020
Abstract Myeloid-derived suppressor cell (MDSC) levels are elevated in patients with cancer and contribute to reduced efficacy of immune checkpoint therapy. MDSC express Bruton's tyrosine kinase (BTK) BTK inhibition ibrutinib, an FDA-approved irreversible inhibitor BTK, leads expansion/function mice significantly improves the antitumor activity anti-PD-1 antibody treatments. Single-cell RNA sequencing (scRNA-seq) was used characterize effect ibrutinib on gene expression...
<p>Comparison of melanoma MDSC to breast (A-B) and head neck (C-D).</p>
<p>Individual UMAP plots melanoma MDSC treated with DMSO control or 5 µM ibrutinib for 4h.</p>
<div>Abstract<p>Myeloid-derived suppressor cell (MDSC) levels are elevated in patients with cancer and contribute to reduced efficacy of immune checkpoint therapy. MDSC express Bruton's tyrosine kinase (BTK) BTK inhibition ibrutinib, an FDA-approved irreversible inhibitor BTK, leads expansion/function mice significantly improves the antitumor activity anti-PD-1 antibody treatments. Single-cell RNA sequencing (scRNA-seq) was used characterize effect ibrutinib on gene expression...
<p>FACS purified MDSC viability after 24h DMSO or ibrutinib treatment.</p>
<p>Expression thresholds for CD14 gene expression.</p>
<p>MDSC isolation via FACS.</p>
<p>Pathway analysis results from IPA of melanoma MDSC treated with DMSO control or 4h ibrutinib.</p>
<p>Analysis of subsets (PMN-MDSC DE vs. double positive MDSC).</p>
<p>Pathway analysis results from IPA of melanoma MDSC treated with DMSO control or 4h ibrutinib.</p>
<p>MDSC isolation via FACS.</p>
<p>Expression thresholds for CD14 gene expression.</p>
<p>Analysis of subsets (PMN-MDSC DE vs. double positive MDSC).</p>
<p>FACS purified MDSC viability after 24h DMSO or ibrutinib treatment.</p>
<p>Comparison of melanoma MDSC to breast (A-B) and head neck (C-D).</p>